384 related articles for article (PubMed ID: 12667887)
1. Altered states: the clinical effects of Ecstasy.
Cole JC; Sumnall HR
Pharmacol Ther; 2003 Apr; 98(1):35-58. PubMed ID: 12667887
[TBL] [Abstract][Full Text] [Related]
2. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.
Thomasius R; Petersen K; Buchert R; Andresen B; Zapletalova P; Wartberg L; Nebeling B; Schmoldt A
Psychopharmacology (Berl); 2003 Apr; 167(1):85-96. PubMed ID: 12632248
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis-Mayfrank E; Daumann J
Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
[TBL] [Abstract][Full Text] [Related]
5. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
McCann UD; Slate SO; Ricaurte GA
Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162
[TBL] [Abstract][Full Text] [Related]
6. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.
Parrott AC; Lasky J
Psychopharmacology (Berl); 1998 Oct; 139(3):261-8. PubMed ID: 9784083
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.
Hanson KL; Luciana M
J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296
[TBL] [Abstract][Full Text] [Related]
8. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA).
Gouzoulis-Mayfrank E; Daumann J; Tuchtenhagen F; Pelz S; Becker S; Kunert HJ; Fimm B; Sass H
J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):719-25. PubMed ID: 10811694
[TBL] [Abstract][Full Text] [Related]
9. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.
Vegting Y; Reneman L; Booij J
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3473-501. PubMed ID: 27568200
[TBL] [Abstract][Full Text] [Related]
10. [Acute and long-term effects of ecstasy].
Salzmann J; Marie-Claire C; Noble F
Presse Med; 2004 Oct; 33(18 Suppl):24-32. PubMed ID: 15617173
[TBL] [Abstract][Full Text] [Related]
11. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
[TBL] [Abstract][Full Text] [Related]
12. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
13. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
[TBL] [Abstract][Full Text] [Related]
14. Neurological and cognitive alterations induced by MDMA in humans.
Montgomery C; Roberts CA
Exp Neurol; 2022 Jan; 347():113888. PubMed ID: 34624331
[TBL] [Abstract][Full Text] [Related]
15. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
Nervenarzt; 1996 May; 67(5):369-80. PubMed ID: 9005345
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
[TBL] [Abstract][Full Text] [Related]
17. Methylenedioxymethamphetamine (MDMA, "Ecstasy").
Shannon M
Pediatr Emerg Care; 2000 Oct; 16(5):377-80. PubMed ID: 11063374
[TBL] [Abstract][Full Text] [Related]
18. [Ecstasy].
Trkulja V; Lacković Z
Lijec Vjesn; 1997; 119(5-6):158-66. PubMed ID: 9379824
[TBL] [Abstract][Full Text] [Related]
19. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
Karlsen SN; Spigset O; Slørdal L
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
[TBL] [Abstract][Full Text] [Related]
20. Death by "ecstasy": the serotonin syndrome?
Mueller PD; Korey WS
Ann Emerg Med; 1998 Sep; 32(3 Pt 1):377-80. PubMed ID: 9737504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
